May 31, 2004European Heart JournalOpen Access

Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation

View Full Paper

Ask AI

Bookmark

Why the study?

Do drug-eluting stents reduce adverse events and restenosis compared to non-drug-eluting stents in patients undergoing percutaneous coronary revascularisation?

Structured PICO

Do drug-eluting stents reduce adverse events and restenosis compared to non-drug-eluting stents in patients undergoing percutaneous coronary revascularisation?

Population

Patients undergoing percutaneous coronary revascularisation (discussed in the context of a meta-analysis of drug-eluting stent trials)

Intervention

Drug-eluting stents (sirolimus-eluting and paclitaxel-eluting stents)

Comparator

Non-drug-eluting stents (bare-metal stents)

Outcome

Adverse clinical events and angiographic restenosiscomposite

Limitations

Routine angiographic follow-up artificially increases revascularisations
Studies conducted on low-risk populations limit the ability to detect impact on hard endpoints like death or myocardial infarction
Lack of a standard format to report study findings across trials

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This editorial highlights that drug-eluting stents significantly reduce restenosis and repeat revascularization compared to bare-metal stents, supporting their role as the new gold standard in percutaneous coronary intervention.

Cite This Study

Antonio Colombo (2004) studied this question.

synapsesocial.com/papers/6a8d1626cc9a452e0590660f https://doi.org/10.1016/j.ehj.2004.04.004

View Full Paper

Ask AI

Bookmark

Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider